Prof. Riedemann received his M.D. training at Freiburg - and Stanford University (Germany / USA). He spent several years in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School where he still holds a Professorship for Experimental Surgery. He specialized as Intensive Care Physician and has been appointed Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena. His research has been awarded with several national and international awards (e.g. Hugo-Schottmüller-Award, Hans-Liniger-Award etc.) and he has received extensive extra mural funding and published over 50 high ranked scientific publications. He actively serves as member on 2 Boards of Directors of large scientific governmental programs. As founder of InflaRx, Prof. Riedemann combines in-depth basic science experience and advanced clinical knowledge in the field of inflammation and acute care. Prof. Riedemann is heading InflaRx as CEO since 2007.
Prof. Renfeng Guo, M.D.
Chief Scientific Officer and Founder
Prof. Guo received his M.D. degree from Norman Bethune Medical School in China. He did his post-doctoral training in the laboratory of Prof. Peter Ward in Ann Arbor at the University of Michigan. He has been a junior and senior faculty member at the University of Michigan since 2001 where he still holds an Adjunct Research Associate Professor position. He achieved over 50 high impact publications in the field of inflammation research. He holds an Honorary Professorship at Beijing Institute of Basic Sciences. As founder and CSO of InflaRx, Prof. Guo leverages his expertise in antibody research and inflammation, bringing together a worldwide recognized experience in the field of acute inflammation, sepsis and lung injury. Prof. Guo is heading InflaRx's scientific development as CSO since 2007.
Arnd Christ, MBA
Chief Financial Officer
Arnd Christ has served as InflaRx's Chief Financial Officer since April 2015. He has a 17-years track record as CFO in private and public biotech companies. Before joining InflaRx, Arnd Christ was CFO of Medigene AG (listed), Munich, Novimmune SA, Geneva and Probiodrug AG, Halle, Germany. During this time, Arnd Christ played a pivotal role in developing the companies by conducting numerous corporate transactions such as raising capital, licensing deals with pharmaceutical companies, asset sales and managing successfully turn-arounds. Before joining the biotech industry, Arnd Christ served as Financial Director in various companies of the former Hoechst Group in Germany and the UK. Arnd has a degree in business & administration from the University of Würzburg, Germany.
Othmar Zenker, M.D.
Chief Medical Officer
Othmar Zenker received his M.D. from the Kiel Medical School in Germany in 1990 and resembles more than 20 years experience in clinical drug development within various internationally operating companies. He served in different lead positions within clinical programs of companies such as Wyeth Pharmaceuticals and CSL Behring. He previousely held a position as Global Head of Immunology at CSL Behring before joining our management team in 2013. Dr. Zenker was heading the clinical R&D programs of InflaRx since 2013 until 2017 as Head of Clinical R&D and has taken on responsibilities for various innovative clinical development programs at InflaRx. He was promoted to Chief Medical Officer in 2017.
Maria Habel, Ph.D.
Head of Pre-Clinical R&D
Maria Habel studied biochemistry and received her Ph.D. in Science from the Graduate School for Cellular and Biomedical Science of the University Bern, Switzerland, in 2008. She joined InflaRx in 2008 as Head of Laboratory and was part of the initial InflaRx team to start the company. Dr. Habel is heading all pre-clinical R&D programs of InflaRx since 2013 and has taken on responsibilities for various scientific projects related to the complement system as well as to the characterization of the lead drug candidates. In addition, Dr. Habel has been appointed Head of Quality Control within the companies GMP manufacturing activities since 2010.